Dare Bioscience, Inc. Operating Cash Flow
Dare Bioscience, Inc. (DARE) reported Operating Cash Flow of -$12.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Dare Bioscience, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.78M.
- Dare Bioscience, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.52M.
- Dare Bioscience, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $1.44M, a 72.78% decline year-over-year.
- Dare Bioscience, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$442.13K.
- Dare Bioscience, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$9.89M, a 280.61% decline from fiscal 2024.
- Dare Bioscience, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $5.47M.
- Dare Bioscience, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$38.86M.
- Dare Bioscience, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$18.09M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$6.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$12.30M 10-Q · filed 2026-08-13 | -$10.85M derived: sum of 3 quarters · filed 2026-08-13 | -$11.29M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$5.52M 10-Q · filed 2026-05-14 | -$4.08M derived: sum of 2 quarters · filed 2026-05-14 | -$4.52M derived: sum of 3 quarters · filed 2026-05-14 | -$9.94M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.00M derived: sum of 2 quarters · filed 2026-03-26 | -$4.42M derived: sum of 3 quarters · filed 2026-08-13 | -$9.89M 10-K · filed 2026-03-26 | |
| 2025-09-30 | -$442.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$5.86M derived: sum of 2 quarters · filed 2026-08-13 | -$11.33M 10-Q · filed 2025-11-13 | -$6.02M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$5.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$10.89M 10-Q · filed 2026-08-13 | -$5.58M derived: sum of 3 quarters · filed 2026-08-13 | -$11.51M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$5.47M 10-Q · filed 2026-05-14 | -$164.63K derived: sum of 2 quarters · filed 2026-05-14 | -$6.09M derived: sum of 3 quarters · filed 2026-05-14 | $6.82M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$618.17K derived: sum of 2 quarters · filed 2026-03-26 | $12.29M derived: sum of 3 quarters · filed 2026-03-26 | $5.47M 10-K · filed 2026-03-26 | $5.39M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$5.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.98M derived: sum of 2 quarters · filed 2025-11-13 | $167.64K 10-Q · filed 2025-11-13 | -$8.01M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $6.09M 10-Q · filed 2025-08-14 | -$2.09M derived: sum of 3 quarters · filed 2025-08-14 | -$10.06M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$6.81M 10-Q · filed 2025-05-13 | -$14.99M derived: sum of 2 quarters · filed 2025-05-13 | -$22.97M derived: sum of 3 quarters · filed 2025-05-13 | -$29.55M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$16.15M derived: sum of 2 quarters · filed 2025-03-31 | -$22.74M derived: sum of 3 quarters · filed 2025-03-31 | -$38.86M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$7.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$14.56M derived: sum of 2 quarters · filed 2024-11-14 | -$30.68M 10-Q · filed 2024-11-14 | -$36.57M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$6.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$22.70M 10-Q · filed 2024-08-12 | -$28.60M derived: sum of 3 quarters · filed 2024-08-12 | -$20.00M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$16.12M 10-Q · filed 2024-05-14 | -$22.01M derived: sum of 2 quarters · filed 2024-05-14 | -$13.41M derived: sum of 3 quarters · filed 2024-05-14 | -$21.86M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.70M derived: sum of 2 quarters · filed 2024-03-28 | -$5.74M derived: sum of 3 quarters · filed 2024-03-28 | -$18.09M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $8.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $151.72K derived: sum of 2 quarters · filed 2023-11-09 | -$12.19M 10-Q · filed 2023-11-09 | -$22.11M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$8.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$20.79M 10-Q · filed 2023-08-10 | -$30.71M derived: sum of 3 quarters · filed 2023-08-10 | -$29.39M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$12.34M 10-Q · filed 2023-05-11 | -$22.26M derived: sum of 2 quarters · filed 2023-05-11 | -$20.94M derived: sum of 3 quarters · filed 2023-05-11 | -$32.73M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$8.60M derived: sum of 2 quarters · filed 2023-03-30 | -$20.39M derived: sum of 3 quarters · filed 2023-03-30 | -$28.76M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$10.47M derived: sum of 2 quarters · filed 2022-11-10 | -$18.85M 10-Q · filed 2022-11-10 | -$28.04M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$11.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$20.17M 10-Q · filed 2022-08-09 | -$29.36M derived: sum of 3 quarters · filed 2022-08-09 | -$34.72M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$8.38M 10-Q · filed 2022-05-12 | -$17.57M derived: sum of 2 quarters · filed 2022-05-12 | -$22.93M derived: sum of 3 quarters · filed 2022-05-12 | -$27.01M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$14.55M derived: sum of 2 quarters · filed 2022-03-31 | -$18.64M derived: sum of 3 quarters · filed 2022-03-31 | -$25.23M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$5.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$9.44M derived: sum of 2 quarters · filed 2021-11-10 | -$16.04M 10-Q · filed 2021-11-10 | -$19.85M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$4.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$10.68M 10-Q · filed 2021-08-12 | -$14.49M derived: sum of 3 quarters · filed 2021-08-12 | -$17.67M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$6.60M 10-Q · filed 2021-05-13 | -$10.41M derived: sum of 2 quarters · filed 2021-05-13 | -$13.59M derived: sum of 3 quarters · filed 2021-05-13 | -$16.60M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$6.99M derived: sum of 2 quarters · filed 2021-03-30 | -$10.01M derived: sum of 3 quarters · filed 2021-03-30 | -$13.32M 10-K · filed 2021-03-30 | |
| 2019-09-30 | -$3.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$6.20M derived: sum of 2 quarters · filed 2020-11-12 | -$9.51M 10-Q · filed 2020-11-12 | -$12.22M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$3.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$6.33M 10-Q · filed 2020-08-12 | -$9.04M derived: sum of 3 quarters · filed 2020-08-12 | -$11.79M derived: sum of 4 quarters · filed 2020-08-12 | |
| 2019-03-31 | -$3.31M 10-Q · filed 2020-05-14 | -$6.02M derived: sum of 2 quarters · filed 2020-05-14 | -$8.77M derived: sum of 3 quarters · filed 2020-05-14 | -$11.46M derived: sum of 4 quarters · filed 2020-05-14 | |
| 2018-12-31 | -$2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$5.46M derived: sum of 2 quarters · filed 2020-03-27 | -$8.15M derived: sum of 3 quarters · filed 2020-03-27 | -$10.27M 10-K · filed 2020-03-27 | |
| 2018-09-30 | -$2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$5.44M derived: sum of 2 quarters · filed 2019-11-12 | -$7.56M 10-Q · filed 2019-11-12 | -$8.52M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | -$2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$4.81M 10-Q · filed 2019-08-14 | -$5.77M derived: sum of 3 quarters · filed 2019-08-14 | -$7.19M derived: sum of 4 quarters · filed 2019-08-14 | |
| 2018-03-31 | -$2.12M 10-Q · filed 2019-05-14 | -$3.08M derived: sum of 2 quarters · filed 2019-05-14 | -$4.50M derived: sum of 3 quarters · filed 2019-05-14 | ||
| 2017-12-31 | -$961.07K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$2.38M derived: sum of 2 quarters · filed 2019-04-01 | -$2.54M 10-K · filed 2019-04-01 | ||
| 2017-09-30 | -$1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$1.58M 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | -$160.21K 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |